Found 84 articles
Cyrus Biotechnology, Inc. is announcing the release of novel software capabilities to handle protein interactions with DNA & RNA as part of its Cyrus Bench® platform.
Cyrus Biotechnology Announces Release of Antibody Structure Prediction Software for Biologics Drug Development and Discovery
Cyrus Biotechnology, Inc. announced the release of a novel Antibody Structure Prediction Software tool as part of its Cyrus Bench® platform.
Cyrus Biotechnology and OpenEye Scientific Software Announce Collaboration and Cheminformatics Integration to Expedite New Drug Design and Development with Cyrus Bench Platform
Cyrus Biotechnology, Inc. announced today that through a collaboration with OpenEye Scientific Software, Inc., a leader in computational molecular design, capabilities have been developed that allow small molecule ligands to be processed and used with Rosetta and within the Cyrus Bench® platform for computational protein drug design.
Cyrus Biotechnology, Inc. announced the general release of a new immune screening and prediction tool in their Cyrus Bench® platform.
LADAVRU® NEWS “HOVERINK BIOTECHNOLOGIES SEEKS COMMERCIAL PARTNERING OPPORTUNITIES IN ONCOLOGY SUPPORTIVE THERAPIES AND SEEKS A COMMERCIALIZATION AGREEMENT FOR ITS INVESTIGATIONAL DRUG LADAVRU®”
HOVERINK BIOTECHNOLOGIES, seeks to enter into a licensing agreement for the exclusive rights to commercialize LADAVRU(TM) (Dronabinol for injection) and an oral formulation of LADAVRU®.
Alexandria Venture Investments Launches the Alexandria Seed Capital Platform, a Novel and Innovative Seed-Stage Life Science Funding Model and a Natural Extension of Alexandria LaunchLabs
The Alexandria Seed Capital Platform will be led by Alexandria Venture Investments and supported by a preeminent Advisory Board of seasoned biopharma and venture capital executives from Accelerator Life Science Partners, ARCH Venture Partners, Eli Lilly and Company, Pfizer and Roche.
Cyrus Biotechnology Announces $8M Financing To Expand Computational Drug Discovery Software Platform
Oncorus Appoints Biotech Industry Veteran Cyrus D. Mozayeni, M.D., As President And Chief Business Officer
Highly Potent Autophagy-Inducing Peptides Now Exclusively Available From Novus Biologicals, A Bio-Techne Brand
Cytel Publication In The New England Journal of Medicine Propels Adaptive Design Into The Mainstream Of Medical Research
CTD Holdings To Present "Management Of Niemann-Pick Type C With Intravenous Hydroxypropyl-B-Cyclodextrin" At Ara Parseghian Medical Research Foundation Annual Conference
Cyrus Biotechnology Licenses Advanced Biochemistry Software From Indiana University To Deliver World-Leading Protein Structure Prediction Engine
Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc.'s Nexavar Misses Target In Phase 3 Liver Cancer Trial
FDA Approves Bayer HealthCare, Onyx Pharmaceuticals, Inc.'s NEXAVAR® To Treat Type Of Thyroid Cancer
Industrial Technology Research Institute (ITRI) Release: The World''s Influential Biotech Delegation Gathering in BioBusiness Asia 2011
Molecular Response (MRL) Announced Today the Appointment of Cyrus K. Mirsaidi to Chief Executive Officer
AltheaDx and The Nicholas Conor Institute for Pediatric Cancer Research Announce Molecular Diagnostics Collaboration to Improve the Diagnosis and Treatment of Childhood Cancer